SHR-A2102 + adebrelimab + cetuximab

**SHR-A2102 + adebrelimab + cetuximab** is an investigational combination regimen being studied for the treatment of advanced or metastatic non-small cell lung cancer and other solid tumors. Each component has a distinct modality and mechanism: - SHR-A2102: a novel antibody-drug conjugate under evaluation in early-phase trials for solid tumors; specific target is not disclosed, but it is administered intravenously[4][7]. - Adebrelimab: a fully humanized IgG4 monoclonal antibody targeting programmed cell death-ligand 1 (PD-L1), designed to block PD-L1 interaction with PD-1 and B7-1, thereby reactivating T-cell mediated anti-tumor immunity; developed by Hengrui Medicine and administered intravenously[2][5]. - Cetuximab: a chimeric monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR), inhibiting receptor activation and downstream signaling involved in cell proliferation, survival, and metastasis; enhances antibody-dependent cellular cytotoxicity, also administered intravenously[3][6]. This combination is being explored in early clinical trials to assess safety, tolerability, and efficacy.

Other names

ErbituxSHR-1316SHR1316SHR 1316